Illumina (ILMN) Stock Price, News & Analysis

Company Overview

Illumina, Inc. (NASDAQ: ILMN) is a leading provider of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company develops, manufactures and markets next-generation sequencing (NGS) and microarray platforms, consumables and software tools that enable researchers, clinicians and agricultural customers to unlock insights from genomic data. Its product portfolio spans high-throughput sequencing instruments such as NovaSeq, mid-range systems like NextSeq and benchtop devices including MiSeq and iSeq, along with corresponding library preparation kits and reagents.

Illumina’s technologies support a broad array of applications, including whole-genome sequencing, targeted resequencing, transcriptome analysis, epigenetic profiling and genotyping. These solutions are used in academic research, pharmaceutical and biotechnology development, consumer genomics, reproductive health and agrigenomics. The company also offers bioinformatics software and data interpretation services to help customers manage and analyze complex datasets, accelerating discoveries in disease biology, personalized medicine and biomarker development.

Founded in 1998 and headquartered in San Diego, California, Illumina serves a global customer base with regional offices, research and manufacturing sites across North America, Europe, Asia-Pacific and Latin America. Its instruments and consumables are distributed worldwide, supported by a network of application specialists and service engineers. Illumina’s leadership team brings together expertise in genomics, engineering and commercial operations, guiding the company’s strategic focus on expanding access to high-quality genomic data and fostering collaborations across the life sciences community.

Key Stats

• Today's Range: $94.97 to $101.94
• 50-Day Range: $91.69 to $109.88
• 52-Week Range: $68.70 to $156.66
• Volume: 1.25 million shs
• Average Volume: 2.22 million shs
• Market Capitalization: $15.59 billion
• P/E Ratio: 12.76
• Dividend Yield: N/A
• Price Target: $123.06
• Consensus Rating: Hold

Illumina Stock Analysis - MarketRank™

Illumina scored higher than 94% of companies evaluated by MarketBeat, and ranked 58th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Illumina has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 6 buy ratings, 11 hold ratings, and 2 sell ratings.

Upside Potential

Illumina has a consensus price target of $123.06, representing about 22.0% upside from its current price of $100.83.

Amount of Analyst Coverage

Illumina has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.41%

Earnings Growth

Earnings for Illumina are expected to grow by 14.41% in the coming year, from $4.51 to $5.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Illumina is 12.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of Illumina is 12.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.01.

Price to Earnings Growth Ratio

Illumina has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Illumina has a P/B Ratio of 6.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.78% of the outstanding shares of Illumina have been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 1.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Illumina does not currently pay a dividend.

Dividend Growth

Illumina does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

4.78% of the outstanding shares of Illumina have been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 1.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.07

News Sentiment

Illumina has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Illumina this week, compared to 20 articles on an average week.

Search Interest

Only 7 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

MarketBeat Follows

6 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Illumina insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.17% of the stock of Illumina is held by insiders.

Percentage Held by Institutions

89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ILMN Stock Analysis - Frequently Asked Questions

How have ILMN shares performed this year?

Illumina's stock was trading at $133.63 at the beginning of the year. Since then, ILMN stock has decreased by 24.5% and is now trading at $100.83.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Thursday, July, 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina's revenue was down 4.8% compared to the same quarter last year.
Read the conference call transcript.

Does Illumina have any subsidiaries?

The following companies are subsidiaries of Illumina: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 10/01/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ILMN
• CIK: 1110803
• Web: www.illumina.com
• Phone: (858) 202-4500
• Fax: 858-202-4766
• Employees: 9,030
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Illumina: $123.06
• High Price Target: $200.00
• Low Price Target: $80.00
• Potential Upside/Downside: +22.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.21
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.90
• Trailing P/E Ratio: 12.67
• Forward P/E Ratio: 22.26
• P/E Growth: 2.22
• Net Income: -$1.22 billion
• Net Margins: 29.36%
• Pretax Margin: 32.54%
• Return on Equity: 28.93%
• Return on Assets: 10.74%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 1.81
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $4.28 billion
• Price / Sales: 3.60
• Cash Flow: $5.13 per share
• Price / Cash Flow: 19.58
• Book Value: $14.96 per share
• Price / Book: 6.71

Miscellaneous

• Outstanding Shares: 153,700,000
• Free Float: 153,439,000
• Market Cap: $15.43 billion
• Optionable: Optionable
• Beta: 1.43